Tetrahydrogestrinone

Jump to: navigation, search
Tetrahydrogestrinone.png
Tetrahydrogestrinone
Systematic (IUPAC) name
(13S,17S)-13,17-diethyl-17-hydroxy-1,2,6,7,8,13,14,15,16,17- decahydrocyclopenta[a]phenanthren-3-one
Identifiers
CAS number 618903-56-3
ATC code  ?
PubChem  ?
Chemical data
Formula C21H28O2 
Mol. mass 312.46 g/mol
Synonyms Tetrahydrogestrinone, THG
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status

Schedule I(US)

Routes Oral, Intramuscular

WikiDoc Resources for

Tetrahydrogestrinone

Articles

Most recent articles on Tetrahydrogestrinone

Most cited articles on Tetrahydrogestrinone

Review articles on Tetrahydrogestrinone

Articles on Tetrahydrogestrinone in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Tetrahydrogestrinone

Images of Tetrahydrogestrinone

Photos of Tetrahydrogestrinone

Podcasts & MP3s on Tetrahydrogestrinone

Videos on Tetrahydrogestrinone

Evidence Based Medicine

Cochrane Collaboration on Tetrahydrogestrinone

Bandolier on Tetrahydrogestrinone

TRIP on Tetrahydrogestrinone

Clinical Trials

Ongoing Trials on Tetrahydrogestrinone at Clinical Trials.gov

Trial results on Tetrahydrogestrinone

Clinical Trials on Tetrahydrogestrinone at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Tetrahydrogestrinone

NICE Guidance on Tetrahydrogestrinone

NHS PRODIGY Guidance

FDA on Tetrahydrogestrinone

CDC on Tetrahydrogestrinone

Books

Books on Tetrahydrogestrinone

News

Tetrahydrogestrinone in the news

Be alerted to news on Tetrahydrogestrinone

News trends on Tetrahydrogestrinone

Commentary

Blogs on Tetrahydrogestrinone

Definitions

Definitions of Tetrahydrogestrinone

Patient Resources / Community

Patient resources on Tetrahydrogestrinone

Discussion groups on Tetrahydrogestrinone

Patient Handouts on Tetrahydrogestrinone

Directions to Hospitals Treating Tetrahydrogestrinone

Risk calculators and risk factors for Tetrahydrogestrinone

Healthcare Provider Resources

Symptoms of Tetrahydrogestrinone

Causes & Risk Factors for Tetrahydrogestrinone

Diagnostic studies for Tetrahydrogestrinone

Treatment of Tetrahydrogestrinone

Continuing Medical Education (CME)

CME Programs on Tetrahydrogestrinone

International

Tetrahydrogestrinone en Espanol

Tetrahydrogestrinone en Francais

Business

Tetrahydrogestrinone in the Marketplace

Patents on Tetrahydrogestrinone

Experimental / Informatics

List of terms related to Tetrahydrogestrinone


Overview

Tetrahydrogestrinone (often referred to as THG) is an anabolic steroid. It has affinity to the androgen receptor and the progesterone receptor, but not to the estrogen receptor.[1] The drug has been considered a "designer drug", closely related to the banned anabolic steroids gestrinone and trenbolone,[2] and was banned by the Food and Drug Administration (FDA) at the end of 2003.[3]

It was created by Patrick Arnold.

Anecdotal sources and some unpublished SAR studies report that the potency of the drug is outstanding, surpassing, on a milligram per milligram basis, every known synthesized or commercial available anabolic steroid. It was the drug of choice for safe and "invisible" world record breaking in athletics.

The drug was again made public when the United States Anti-Doping Agency was contacted by an anonymous athletics coach, later identified as Trevor Graham, who claimed that several top athletes were using THG and provided the USADA with a syringe containing THG, which the USADA then used to develop a test for the substance.[4]

The USADA identified the Bay Area Laboratory Co-operative (BALCO), an American nutritional supplement company, as the source of THG. The company manufactured the drug through palladium-charcoal catalyzed hydrogenation from gestrinone, a substance used in gynecology for treatment of endometriosis.

THG had been distributed to several leading athletes, including many during the BALCO scandal.

References

  1. Death AK, McGrath KC, Kazlauskas R, Handelsman DJ. Tetrahydrogestrinone is a potent androgen and progestin. J Clin Endocrinol Metab. 2004 May;89(5):2498-500[1]
  2. Oct.2003 FDA statement on THG
  3. THG ban
  4. http://www.abc.net.au/sport/content/200408/s1182730.htm

Navigation WikiDoc | WikiPatient | Popular pages | Recently Edited Pages | Recently Added Pictures

Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs

Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link Here
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
Linked-in.jpg
Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox